- Home
- FORA vs ASRT Comparison
FORA vs ASRT Comparison
Compare FORA & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FORA | ASRT |
|---|---|---|
| Founded | 2014 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.4M | 75.1M |
| IPO Year | N/A | 1997 |
Fundamental Metrics
Financial Performance| Metric | FORA | ASRT |
|---|---|---|
| Price | $2.14 | $0.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 35.5K | ★ 435.2K |
| Earning Date | 11-14-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $28,106,911.00 | ★ $137,354,000.00 |
| Revenue This Year | $47.82 | N/A |
| Revenue Next Year | $10.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 37.47 | 9.22 |
| 52 Week Low | $1.64 | $0.51 |
| 52 Week High | $4.03 | $1.01 |
Technical Indicators
Market Signals| Indicator | FORA | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 46.79 | 49.20 |
| Support Level | $2.11 | $0.75 |
| Resistance Level | $2.20 | $0.80 |
| Average True Range (ATR) | 0.07 | 0.04 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 55.00 | 81.17 |
Price Performance
Historical ComparisonAbout FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.